返回 
加入收藏
贝伐珠单抗联合化疗方案用于晚期胃癌的临床观察
x
请在关注微信后，向客服人员索取文件
| 篇名： | 贝伐珠单抗联合化疗方案用于晚期胃癌的临床观察 |
| TITLE： | |
| 摘要： | 目的：探讨贝伐珠单抗联合化疗方案用于晚期胃癌的临床疗效及毒副反应。方法：84例晚期胃癌患者根据随机数字表法分为联合组与化疗组，各42例。化疗组患者采用FOLFOX 4（奥沙利铂+亚叶酸钙+氟尿嘧啶）化疗方案；联合组患者在化疗基础上加用贝伐珠单抗7.5 mg/kg静脉滴注，d1。两组均以21 d为1个周期，连续观察3个周期。比较两组患者的近期疗效、生存质量改善情况、化疗前后血清肿瘤标志物水平及药物毒副反应发生情况。结果：联合组患者的有效率（57.14％）明显高于化疗组（35.71％），生存质量提高率明显高于化疗组，生存质量降低率也明显低于对照组，差异均有统计学意义（P＜0.05）；化疗后，两组患者的血清癌胚抗原和糖类抗原199水平均较化疗前明显下降，且联合组患者的下降幅度大于化疗组，差异均有统计学意义（P＜0.05）；联合组患者白细胞、血小板、血红蛋白减少及周围神经毒性、恶心呕吐、肝肾功能异常的发生率均高于化疗组，但差异无统计学意义（P＞0.05）。结论：贝伐珠单抗联合化疗方案用于晚期胃癌的临床疗效显著，且不增加毒副反应。 |
| ABSTRACT： | OBJECTIVE： To investigate clinical efficacy and toxic and side effects of bevacizumab combined with chemotherapy in the treatment of advanced gastric cancer. METHODS： 84 patients with advanced gastric cancer were randomly divided into combination group and chemotherapy group， with 42 cases in each group. Chemotherapy group received FOLFOX4 chemotherapy regimen （oxaliplatin+calcium folinate+fluorouracil）； combination group was additionally given bevacizumab 7.5 mg/kg intravenously， d1， on the basis of chemotherapy. A treatment course lasted for 21 d， and both groups received 3 courses of treatment. The short-term efficacy， the quality improvement of life， serum tumor marker before and after chemotherapy and the toxic and side effects were compared between 2 groups. RESULTS： The effective rate in combination group （57.14％） was significantly higher than chemotherapy group （35.71％）， improvement rate of life quality in combination group was higher than chemotherapy group， reduction rate of life quality in combination group was lower than chemotherapy group， the differences were statistically significant （P＜0.05）； after chemotherapy， the serum CEA and CA199 levels were significantly decreased in both groups， the decrease of combination group was more significant than that of chemotherapy， with statistical significance （P＜0.05）. The incidence of decrease in leucocytes， platelet and hemoglobin， periphery neurotoxicity， nausea and vomiting， liver and kidney function in combination group was higher than in chemotherapy， but there was no statistical significance （P＞0.05）. CONCLUSIONS： Bevacizumab combined with chemotherapy is effective in the treatment of advanced gastric cancer and don’t increase toxic and side effects. |
| 期刊： | 2016年第27卷第23期 |
| 作者： | 王丽红，刘迎，杜晓林 |
| AUTHORS： | WANG Lihong，LIU Ying，DU Xiaolin |
| 关键字： | 贝伐珠单抗；化疗；晚期胃癌；疗效；毒副反应 |
| KEYWORDS： | Bevacizumab； Chemotherapy； Advanced gastric cancer； Therapeutic efficacy； Toxic and side effects |
| 阅读数： | 828 次 |
| 本月下载数： | 4 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
